Facilitating Compound Progression of Antiretroviral Agents via Modeling and Simulation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adelson ME, Pacchia AL, Kaul M, Rando RF, Ron Y, Peltz SW, Dougherty JP (2003) Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemother 47(2):501–508
An J, Totrov M, Abagyan R (2004) Comprehensive identification of “druggable” protein ligand binding sites. Genome Inform 15(2):31–41
Arena VC, Sussman NB, Mazumdar S, Yu S, Macina OT (2004) The utility of structure–activity relationship (SAR) models for prediction and covariate selection in developmental toxicity: comparative analysis of logistic regression and decision tree models. SAR QSAR Environ Res 15(1):1–18
Barrett JS, Labbe L, Pfister M (2005) Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet 44(6):591–625
Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines S, A., Petty KJ, Ogren M, Antoni G, Langstrom B, Eskola O, Scheinin M, Solin O, Majumdar A, K., Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55:1007–1012
Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta MU, Gobburu JV (2005) Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 7(3):E503–E512
Bhoopat L, Eiangleng L, Rugpao S, Frankel SS, Weissman D, Lekawanvijit S, Petchjom S, Thorner P, Bhoopat T (2001) In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. Mod Pathol 14(12):1263–1269
Birbeck GL (2005) Human immunodeficiency virus dementia patients in Africa: How many? Who cares? And where to from here? J Neurovirol 11(3):30–33
Blower S, Ma L, Farmer P, Koenig S (2003) Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 3(4):345–353
Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94(13):6971–6976
Caberlotto L, Hurd Y, L., Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R (2003) Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 17:1736–1746
CDER (2004) Innovation and stagnation: Challenge and opportunity on the critical path to new medicinal products. US Food and Drug Administration, USA
Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V (2005) Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7(3):E544–E559
Contrera JF, Maclaughlin P, Hall LH, Kier LB (2005) QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr Drug Discov Technol 2(2):55–67
de Larranaga, GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA (2003) Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 110(2–3):93–98
Dias AS, Bester MJ, Britz RF, Apostolides Z (2006) Animal models used for the evaluation of antiretroviral therapies. Curr HIV Res 4(4):431–446
Dittmar MT, Simmons G, Donaldson Y, Simmonds P, Clapham PR, Schulz TF, Weiss RA (1997) Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR. J Virol 71(7):5140–5147
Douglas SD, Ho WZ, Gettes DR, Cnaan A, Zhao H, Leserman J, Petitto JM, Golden RN, Evans DL (2001) Elevated substance P levels in HIV-infected men. AIDS 15:2043–2045
Ekins S, Obach RS (2000) Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. J Pharmacol Exp Ther 295(2):463–473
Merck & Co., Inc. (2003) Emend patient product information. Merck & CO., Inc., Whitehouse Station, NJ
Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, Nikolic-Djokic D, Colgrove RC, Baker CJ (2004) Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 23(1):15–22
Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Tamul K, Liao D, van der Horst CM, Hall CD, Folds JD (1995) Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am J Psychiatry 152:543–550
Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM (1997) Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry 154:630–634
Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, Brinker-Spence P, Job C, Mercer DE, Wang YL, Cruess D, Dube B, Dalen EAB, T., Bauer R, Petitto JM (2002) Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 159:1752–1759
FDA Guidance (1999) In vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labeling. Fed Regist ( http://www.fda.gov/cber/guidelines.htm )
FDA Guidance (2002) Antiretroviral drugs using plasma HIV RNA measurements—clinical considerations for accelerated and traditional approval. Fed Regist ( http://www.fda.gov/cber/guidelines.htm )
FDA Guidance (2006) Drug interaction studies—study design, data analysis, and implications for dosing and labeling. Fed Regist ( http://www.fda.gov/cber/guidelines.htm )
Gobburu JV, Sekar VJ (2002) Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. Int J Clin Pharmacol Ther 40(7):281–288
Grasela TH, Fiedler-Kelly J, Walawander CA, Owen JS, Cirincione BB, Reitz KE, Ludwig EA, Passarell JA, Dement CW (2005) Challenges in the transition to model-based development. AAPS J 7(2):E488–E495
Greco SJ, Corcoran KE, Cho KJ, Rameshwar P (2004) Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci 9:1782–1793
Hartung HP, Wolters K, Tokya KV (1986) Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol 136:3856–3863
Ho WZ, Cnaan A, Li YH, Zhao H, Lee HR, Song L, Douglas SD (1996) Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res Hum Retroviruses 12:195–198
Ho WZ, Lai JP, Li Y, Douglas SD (2002) HIV enhances substance P expression in human immune cells. FASEB J 16:616–618
Hoschele D (2006) Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro 20(5):535–546
Huang Y, Rosenkranz SL, Wu H (2003) Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci 184(2):165–186
Kagay CR, Porco TC, Liechty CA, Charlebois E, Clark R, Guzman D, Moss AR, Bangsberg DR (2004) Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis 38(Suppl 5):S414–S420
Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, I ND, Essex ME, Mboup S (1999) Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179(1):68–73
Kedzierska K, Crowe SM (2002) The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem 9(21):1893–1903
Keller TH, Pichota A, Yin Z (2006) A practical view of ‘druggability’. Curr Opin Chem Biol 10(4):357–361
Kramer MS (2000) Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression. Neuropeptides 34:255
Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29:385–392
Laeyendecker O, Zhang GW, Quinn TC, Garten R, Ray SC, Lai S, Liu W, Chen J, Yu XF (2005) Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr 38(3):356–362
Lai JP, Ho WZ, Yang JH, Wang X, Song L, Douglas SD (2002) A non-peptide substance P antagonist down regulates SP mRNA expression in human mononuclear phagocytes. J Neuroimmunol 128:101–108
Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD (2001) Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci U S A 98:3970–3975
Lajiness MS, Vieth M, Erickson J (2004) Molecular properties that influence oral drug-like behavior. Curr Opin Drug Discov Dev 7(4):470–477
Lefrere JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, Petit JC, Roudot-Thoraval F (1997) Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 90(3):1133–1140
Liu S, Jiang S (2004) High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 10(15):1827–1843
Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 46(3):291–300
Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD (1998) Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 92:3148–3151
Michelson S, Sehgal A, Friedrich C (2006) In silico prediction of clinical efficacy. Curr Opin Biotechnol 17(6):666–670
Micheva-Viteva S, Pacchia AL, Ron Y, Peltz SW, Dougherty JP (2005) Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob Agents Chemother 49(12):5185–5188
Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL (2005) How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 32(2):185–197
Parniak MA, Min KL, Budihas SR, Le Grice SF, Beutler JA (2003) A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 322(1):33–39
Parsons JT, Rosof E, Punzalan JC, Di Maria L (2005) Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDS 19(1):31–39
Phillips S, Granade TC, Pau CP, Candal D, Hu DJ, Parekh BS (2000) Diagnosis of human immunodeficiency virus type 1 infection with different subtypes using rapid tests. Clin Diagn Lab Immunol 7(4):698–699
Pluymers W, De Clercq E, Debyser Z (2001) HIV-1 integration as a target for antiretroviral therapy: a review. Curr Drug Targets Infect Disord 1(2):133–149
Rachlis A, Palmer R, Doswell M (1998) Improved survival time and CD4 slope associated with recent advances in HIV antiretroviral therapy. In: Fifth conference on retroviruses and opportunistic infections, Foundation for Retrovirology and Human Health, Chicago IL, 1–15 Feb 1998
Renjifo B, Gilbert P, Chaplin B, Msamanga G, Mwakagile D, Fawzi W, Essex M (2004) Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 18(12):1629–1636
Centers for Disease Control and Prevention (2001) Revised guidelines for HIV counseling, testing, and referral. Morb Mortal Wkly Rep 50(RR19):1–58
Richardt AM, Benigni R (2002) AI and SAR approaches for predicting chemical carcinogenicity: survey and status report. SAR QSAR Environ Res 13(1):1–19
Riecke K, Schulz TG, Shakibaei M, Krause B, Chahoud I, Stahlmann R (2000) Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology 62(5):291–300
Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C (2005) A pharmacokinetic–pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 78(5):508–519
Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E (2006) A pharmacokinetic–pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 42(2):183–191
Rupniak NM (2002a) Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr Opin Investig Drugs 3:257–261
Rupniak NM (2002b) New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can J Physiol Pharmacol 80:489–494
Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54:285–322
Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2006) Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36(7):567–580
Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour HH, Jr. (2002) Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 30(2):154–158
Tsai CC, Follis KE, Grant RF, Nolte RE, Bartz CR, Benveniste RE, Sager PR (1993) Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 6(10):1086–1092
Vernon JA, Hughen WK, Johnson SJ (2005) Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions. Health Care Manag Sci 8(2):167–179
Votano JR (2005) Recent uses of topological indices in the development of in silico ADMET models. Curr Opin Drug Discov Dev 8(1):32–37
Wainberg MA (2004) HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl 3):S63–S68
Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK (2001) Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4(5):348–361